Cancer Therapy

Light infusion technology phase I results reported in journal

Published in Cancer Weekly, November 11th, 2003

Light Sciences announced that phase I clinical trial results using the light infusion technology (Litx) treatment with the drug LS11 have been published.

The study, entitled "A Multicenter Phase I Safety Study of Intratumoral Photoactivation of Talaporfin Sodium (LS11) in Patients with Refractory Solid Tumors," is authored by a 10-member international research team led by Robert Lustig, MD, department of radiation oncology, Hospital of the University of Pennsylvania, Philadelphia.

The study appeared in the October 15, 2003, issue of the journal "Cancer."

Litx is designed to treat localized disease and is initially being studied...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-11-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry